ClinicalTrials.gg
CompletedNCT02095158Updated Nov 18, 2019Results posted

A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

A Phase 3 interventional study of Oxymetazoline HCL Cream 1.0% in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.

Enrollment
2nd of 52
440 · median 52
Started
2014
with 5 others
Phase 3
5 of 55
none open now
Registered
15th of 55
by date
Lead sponsor
7 of 55
Allergan

Among the 55 studies in Erythema with a site in United States, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 15th registered.

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

Browse Erythema studies →

Open to participants now

8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Erythema with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.

03

Conditions studied

  • Erythema
  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion criteria

Exclusion Criteria:

  • Current treatment with monoamine oxidase (MAO) inhibitors
  • Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Oxymetazoline HCL Cream 1.0%

    Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.

    Drug: Oxymetazoline HCL Cream 1.0%

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Related Adverse Events

    An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.

    Time frame: 56 Weeks

Secondary outcomes

  1. Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales

    The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 6-hour evaluation period (hours 3 and 6) post-dose.

    Time frame: Baseline, Day 1 Hours 3 and 6, Week 4 Predose and Hours 3 and 6, Week 12 Predose, Week 26 Predose and Hours 3 and 6, Week 39 Predose, Week 52 Predose and Hours 3 and 6, Week 54 Predose

07

Results

Posted Sep 21, 2016

Participant flow

Participant flow — Overall Study
MilestoneOxymetazoline HCL Cream 1.0%
Started440
Completed365
Not completed75
Withdrew: Adverse event14
Withdrew: Lack of efficacy3
Withdrew: Pregnancy1
Withdrew: Lost to follow-up20
Withdrew: Personal reasons35
Withdrew: Protocol violation1
Withdrew: Other miscellaneous reasons1

Outcome measures

PrimaryPercentage of Participants With Treatment-Related Adverse Events

An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.

Time frame:
56 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Related Adverse Events
percentage of participantsOxymetazoline HCL Cream 1.0%
Percentage of Participants With Treatment-Related Adverse Events8.2
SecondaryPercentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales

The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 6-hour evaluation period (hours 3 and 6) post-dose.

Time frame:
Baseline, Day 1 Hours 3 and 6, Week 4 Predose and Hours 3 and 6, Week 12 Predose, Week 26 Predose and Hours 3 and 6, Week 39 Predose, Week 52 Predose and Hours 3 and 6, Week 54 Predose
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales
percentage of participantsOxymetazoline HCL Cream 1.0%
Day 1 (Hour 3)11.6
Day 1 (Hour 6)17.8
Week 4 (Predose)1.2
Week 4 (Hour 3)19.5
Week 4 (Hour 6)23.0
Week 12 (Predose)6.1
Week 26 (Predose)6.5
Week 26 (Hour 3)34.7
Week 26 (Hour 6)38.1
Week 39 (Predose)9.5
Week 52 (Predose)11.2
Week 52 (Hour 3)36.7
Week 52 (Hour 6)43.4
Week 54 (Predose)12.1

Adverse events

Collected over Up to 56 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxymetazoline HCL Cream 1.0%—15/440 (3.4%)0/440 (0%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventOxymetazoline HCL Cream 1.0%
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/440
Angina pectorisCardiac disorders1/440
Coronary artery diseaseCardiac disorders1/440
Chest painGeneral disorders1/440
CholecystitisHepatobiliary disorders1/440
AppendicitisInfections and infestations1/440
CellulitisInfections and infestations1/440
Chronic sinusitisInfections and infestations1/440
SepsisInfections and infestations1/440
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/440

Baseline characteristics

Age, Customized
Age, Customized(participants)Oxymetazoline HCL Cream 1.0%
18 to 64 years370
≥ 65 years70
Sex: Female, Male
Sex: Female, Male(Participants)Oxymetazoline HCL Cream 1.0%
Female335
Male105
08

Study locations

1 site
  • Portland, Oregon, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2014
First posted
Mar 24, 2014
Start
Apr 2014
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Results first posted
Sep 21, 2016
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02095158
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 24, 2014
Start date
Apr 2014
Primary completion
Aug 2015
Completion
Sep 2015
Results posted
Sep 21, 2016
Last update
Nov 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion